These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12631633)

  • 1. Drug-eluting stents: potential applications for peripheral arterial occlusive disease.
    Duda SH; Poerner TC; Wiesinger B; Rundback JH; Tepe G; Wiskirchen J; Haase KK
    J Vasc Interv Radiol; 2003 Mar; 14(3):291-301. PubMed ID: 12631633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-eluting stents in peripheral vascular disease: eliminating restenosis.
    Ellozy SH; Carroccio A
    Mt Sinai J Med; 2003 Nov; 70(6):417-9. PubMed ID: 14647877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on drug-eluting stents for prevention of restenosis.
    Lee CH; Tan HC; Lim YT
    Asian Cardiovasc Thorac Ann; 2006 Feb; 14(1):75-82. PubMed ID: 16432127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel-eluting stents: current clinical experience.
    Grube E; Buellesfeld L
    Am J Cardiovasc Drugs; 2004; 4(6):355-60. PubMed ID: 15554720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
    Stone GW; Moses JW; Ellis SG; Schofer J; Dawkins KD; Morice MC; Colombo A; Schampaert E; Grube E; Kirtane AJ; Cutlip DE; Fahy M; Pocock SJ; Mehran R; Leon MB
    N Engl J Med; 2007 Mar; 356(10):998-1008. PubMed ID: 17296824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-eluting stents for infrainguinal occlusive disease: progress and challenges.
    Tepe G
    Semin Vasc Surg; 2006 Jun; 19(2):102-8. PubMed ID: 16782516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of sirolimus versus paclitaxel eluting stents for treatment of coronary in-stent restenosis.
    Airoldi F; Briguori C; Iakovou I; Stankovic G; Biondi-Zoccai G; Carlino M; Chieffo A; Montorfano M; Cosgrave J; Michev I; Rogacka R; Sangiorgi GM; Colombo A
    Am J Cardiol; 2006 Apr; 97(8):1182-7. PubMed ID: 16616023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-eluting stents: clinical experiences and perspectives.
    Grube E; Gerckens U; Buellesfeld L
    Minerva Cardioangiol; 2002 Oct; 50(5):469-73. PubMed ID: 12384629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-eluting stent: the emerging technique for the prevention of restenosis.
    Sheiban I; Carrieri L; Catuzzo B; Destefanis P; Oliaro E; Moretti C; Trevi GP
    Minerva Cardioangiol; 2002 Oct; 50(5):443-53. PubMed ID: 12384626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-eluting stents: from randomized trials to the real world.
    Saia F; Degertekin M; Lemos PA; Serruys PW
    Minerva Cardioangiol; 2004 Oct; 52(5):349-63. PubMed ID: 15514571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-stent stenosis: pathology and implications for the development of drug eluting stents.
    Bennett MR
    Heart; 2003 Feb; 89(2):218-24. PubMed ID: 12527687
    [No Abstract]   [Full Text] [Related]  

  • 13. C-Reactive protein, clinical outcome, and restenosis rates after implantation of different drug-eluting stents.
    Gaspardone A; Versaci F; Tomai F; Citone C; Proietti I; Gioffrè G; Skossyreva O
    Am J Cardiol; 2006 May; 97(9):1311-6. PubMed ID: 16635602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients.
    Dibra A; Kastrati A; Mehilli J; Pache J; Schühlen H; von Beckerath N; Ulm K; Wessely R; Dirschinger J; Schömig A;
    N Engl J Med; 2005 Aug; 353(7):663-70. PubMed ID: 16105990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-eluting stents: a new treatment in the prevention of restenosis. Part I: Experimental studies.
    Salu KJ; Bosmans JM; Bult H; Vrints CJ
    Acta Cardiol; 2004 Feb; 59(1):51-61. PubMed ID: 15030135
    [No Abstract]   [Full Text] [Related]  

  • 16. ABT-578-eluting stents. The promising successor of sirolimus- and paclitaxel-eluting stent concepts?
    Buellesfeld L; Grube E
    Herz; 2004 Mar; 29(2):167-70. PubMed ID: 15054589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Release profiles in drug-eluting stents: issues and uncertainties.
    Venkatraman S; Boey F
    J Control Release; 2007 Jul; 120(3):149-60. PubMed ID: 17582635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the drug-eluting stent trials.
    Coolong A; Kuntz RE
    Am J Cardiol; 2007 Sep; 100(5A):17K-24K. PubMed ID: 17719349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.
    Poerner TC; Otto S; Gassdorf J; Janiak F; Danzer C; Ferrari M; Figulla HR
    EuroIntervention; 2011 May; 7 Suppl K():K93-9. PubMed ID: 22027737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-eluting stents: preventing restenosis.
    Slavin L; Chhabra A; Tobis JM
    Cardiol Rev; 2007; 15(1):1-12. PubMed ID: 17172878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.